Practice acquisition for Independent pharmacy
Acquisition financing for independent pharmacy
Direct answer
Acquisition financing for an independent pharmacy funds the purchase of the business or its prescription files, underwritten against 3 measures: script count, gross margin after direct and indirect remuneration, and payer mix. Practition Finance explains those mechanics and, by state, refers the request to funding partners.
As of October 2026
An independent pharmacy acquisition is rarely a purchase of the storefront alone. In most deals the value sits in the script files, the recurring prescriptions a patient population brings back month after month, and a lender wants to see how durable that file base is before it prices anything against future volume. A pharmacy with a concentrated group of chronic-medication patients reads differently than one built on episodic fills.
Buyers coming from a chain pharmacy background sometimes underestimate how much a PBM contract set determines what the acquired pharmacy will actually collect. The seller's existing contracts, and the reimbursement rates and direct and indirect remuneration fees attached to them, transfer with the business in most structures, and a lender wants to see what margin survives those terms before it commits to a purchase price. This is the single most common reason an acquisition gets repriced mid-diligence.
The credit decision also weighs payer mix and days in accounts receivable the way any insurance-billed healthcare business is underwritten. A pharmacy heavily weighted toward Medicare Part D and Medicaid claims carries a different reimbursement timeline than one with a larger commercial payer share, and a lender factors that into how it structures working capital alongside the acquisition note itself.
Why this program fits your situation
Acquisition financing fits an independent pharmacy purchase where the file base, the PBM contracts, and the margin after remuneration fees all hold up to scrutiny
Script count and file retention are documented, not estimated
A lender wants actual script counts by month for the trailing 24 to 36 months, broken out by new versus refill volume, along with whatever the seller can show about patient retention after past staffing or ownership changes. A buyer walking in with a seller's verbal claim about volume rather than dispensing system reports should expect the lender to require that data directly before underwriting proceeds. Pharmacies with stable or growing script counts and low patient churn present the strongest acquisition case.
Gross margin after direct and indirect remuneration is calculated, not assumed
DIR fees are deducted from reimbursement after the point of sale, sometimes months later, which means a pharmacy's apparent margin at the register overstates what it actually nets. A buyer who underwrites the deal off gross reimbursement without netting out DIR exposure will misprice the acquisition and the working capital it needs to carry. The stronger acquisition file includes a true net margin calculation built from the seller's actual remittance history rather than published reimbursement schedules.
PBM contract terms transfer cleanly or are renegotiated before closing
Some PBM contracts require a formal assignment or a new credentialing process when ownership changes, which can create a reimbursement gap between closing and full contract transfer. A buyer who has confirmed with each major PBM how the transition will be handled, and who has budgeted working capital to cover any gap, presents a materially lower-risk file than one who assumes the contracts simply carry over unchanged. This is a step lenders increasingly ask about directly.
Payer mix and days in accounts receivable are within a workable range
A pharmacy collecting primarily through point-of-sale claims has a different working capital profile than one with a meaningful third-party billing or long-term care component running on invoice terms. Lenders check days in accounts receivable against the acceptable band and want to know how much of the payer mix sits in slower-paying channels before sizing the acquisition note and any accompanying working capital facility. A payer mix skewed heavily toward slow-paying channels invites a more conservative structure.
Directional terms for a file like yours
What a lender checks on an independent pharmacy acquisition file
| What it measures | Market range | Confidence | How to read it |
|---|---|---|---|
| Days in accounts receivable on third-party and LTC billing | Under 30 high performing, 30 to 40 acceptable, over 50 a problem6 | VerifiedAugust 2026 | A pharmacy with billing components outside point-of-sale claims is checked against this band to see how much of its receivable base is collecting on time. |
| Credentialing lag if PBM re-enrollment is required | 60 to 120 days7 | DirectionalAugust 2026 | Where a PBM contract requires re-credentialing after a change of ownership, this is the range of delay a buyer should plan working capital around. |
| Denial rate on claims inherited from the prior owner | Under 5% top quartile, 8% to 10% average8 | VerifiedAugust 2026 | A pharmacy with a denial rate above this band signals billing or documentation issues that can carry into the buyer's first months of ownership. |
| Net collection rate as a margin check | 96%8 | VerifiedAugust 2026 | Net collections at or above this benchmark support the margin assumptions a buyer is basing the purchase price on. |
| Working capital cap added to an acquisition note | Up to 15% of the transaction, capped at $200,0009 | VerifiedAugust 2026 | This is the range one lender adds to an acquisition loan to cover inventory buildup and the gap in reimbursement timing after closing. |
| SBA maximum loan size for the combined purchase | $5,000,000, guaranty 85% to $150,000 and 75% above10 | VerifiedAugust 2026 | Most independent pharmacy acquisitions, including inventory and working capital, fit inside this SBA 7(a) ceiling. |
These are ranges the market publishes, current as of the date beside each one. None of it is a quote, an offer, or an indication of terms.
The 3 things that cost owners here
Margin was underwritten off gross reimbursement, not net of DIR fees
DIR fee exposure has grown enough in recent years that a pharmacy's headline margin and its actual net margin can differ meaningfully. Buyers who price an acquisition off the seller's point-of-sale reimbursement figures without pulling the actual remittance history, net of retroactive DIR deductions, sometimes discover after closing that the margin supporting their debt service assumptions was overstated. Requesting 12 to 24 months of net remittance detail before finalizing price is the check that catches this.
PBM contract transfer was assumed rather than confirmed in writing
Not every PBM contract assigns automatically to a new owner, and some require a lapse-free re-credentialing process that can take weeks. A buyer who assumes reimbursement continues uninterrupted at closing, without confirming the transfer mechanism with each major PBM in writing, risks a cash flow gap right when the acquisition note's first payments are due. Building a contingency into the working capital request covers this even when the transfer goes smoothly.
Script file concentration in a small number of prescribers was not tested
A pharmacy where a large share of chronic-medication volume traces back to referrals from one or two prescribing practices carries a concentration risk that does not show up in a simple script count. If one of those referral relationships weakens after the ownership change, the file base the acquisition price was built on can erode quickly. Asking the seller to break down script volume by referring prescriber before finalizing the purchase price surfaces this risk while it is still negotiable.
Run your numbers
Model debt service on a pharmacy acquisition
Check a pharmacy purchase price and working capital add-on against projected net margin and payer mix
Open the calculatorWhat owners ask about this combination
01Can an acquisition loan cover both the pharmacy business and its inventory?
Yes. Most acquisition structures for independent pharmacy finance the purchase price, the inventory at closing, and a working capital allowance in one note, similar to how other healthcare business acquisitions are structured. The inventory valuation at closing is typically confirmed by a physical count rather than the seller's book value. Practition Finance explains how a lender typically splits those components before the offer is finalized.
02What happens to PBM contracts when pharmacy ownership changes?
It depends on the specific PBM and contract terms. Some allow assignment to the new owner with notice, others require full re-credentialing before reimbursement resumes at the buyer's new NPI. That difference changes how much working capital a buyer needs at closing. Practition Finance explains how to confirm this with each PBM before the purchase agreement is signed rather than after.
03How do lenders treat DIR fees when underwriting a pharmacy acquisition?
Lenders that specialize in pharmacy lending typically require net remittance history rather than gross reimbursement figures, since direct and indirect remuneration fees are deducted after the point of sale and can be substantial. A buyer presenting only gross numbers should expect a lender to request the netted figures before final underwriting. Practition Finance explains what documentation a specific lender requires up front.
04Is script file concentration a disqualifying factor for acquisition financing?
It is not automatically disqualifying, but it changes how conservatively the deal is structured. A pharmacy with volume concentrated among a small number of referring prescribers may see a lower advance rate or a larger working capital cushion required. Practition Finance explains how a specific lender weighs that concentration against the rest of the file.
05Does payer mix affect the size of the working capital add-on?
Yes. A pharmacy with a larger share of claims moving through slower-paying channels, including long-term care and certain third-party billing arrangements, typically needs a larger working capital allowance layered onto the acquisition note than one running primarily on point-of-sale claims. Practition Finance explains how that mix is factored into the total financing request before it goes to a lender.
Sources
- 1CMS
- 2SBA
- 3National Community Pharmacists Association
- 4GAO
- 5MGMA
- 6MGMA and HFMA aligned sources
- 7Crestmont
- 8MGMA-cited
- 91stmedfinancial.com
- 10SBA-derived calculators
Run an independent pharmacy acquisition through a Fit Check before the purchase price and working capital request are finalized